Skip to content
MarketScale
‹ Back to IndustriesSciences

Leaders Driving Change: SXSW 2019 Podcast Series

More than 100 people move to Austin, Texas each day on average. Quickly becoming a national city, the state capital is truly a melting pot of business, culture and personality. For one week each year, this identity rises to a new level for SXSW 2019. Thought leaders from the world of business, politics, food, film,…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Software And Technology · Sxsw 2019Sxsw Podcast
Share

Key takeaways

01

More than 100 people move to Austin, Texas each day on average.

02

Quickly becoming a national city, the state capital is truly a melting pot of business, culture and personality.

03

For one week each year, this identity rises to a new level for SXSW 2019.

More than 100 people move to Austin, Texas each day on average. Quickly becoming a national city, the state capital is truly a melting pot of business, culture and personality. For one week each year, this identity rises to a new level for SXSW 2019. Thought leaders from the world of business, politics, food, film, music and more descend upon the city for discussions on the pressing topics of these fields.

MarketScale caught up with 10 of these experts to get a taste of this year’s event from multiple perspectives.

Stay tuned for our three-part podcast series coming out March 11, 13 and 15.

Adrienne Lawrence

SXSW brings together people from extremely varied fields. From music and film to food and technology, expertise comes from just about everywhere. Adrienne Lawrence brings her own expansive background to this year’s conference. As a former sports television host for ESPN and a lawyer, Lawrence brings a perspective that few others can provide on the legal side of sports among other topics.

We got her thoughts on the current outlook for women in sports media and her work with Madden NFL esports.

Currently, Lawrence collaborates with BuzzFeed and the Young Turks in Los Angeles, California.

We're at #SXSW! Thanks to @AdrienneLaw for joining us on the podcast. Stay tuned to hear what she had to say! pic.twitter.com/UMIJqW7EN5
— MarketScale (@MarketScale) March 8, 2019

Heather Watson

The workforce and work space are changing. This much is clear, but what is driving this change and what impact will it have on the future? Heather Watson, behavioral designer for the Center for Generational Kinetics, LLC, has been researching how Gen Z will change the global economy, and what the next wave of workers expects from the job market, working environment and more.

She will also be conducting a session on the state of marketing in the wine industry and how the field can better reach a millennial audience.

Thank you @HwBoost for joining us on the podcast at #SXSW! pic.twitter.com/lr1SbyQnYJ
— MarketScale (@MarketScale) March 8, 2019

Tatyana Kanzaveli

CEO and Founder of Open Health Network Tatyana Kanzaveli stands at the forefront of two burgeoning industries today. She is at SXSW 2019 to explain how blockchain’s use in healthcare is more than just hype and joined the MarketScale podcast to get into the specifics of its impact.

Didrik Fjeldstad

Multiple languages can be heard by those who walk around Austin at any given time, but especially during SXSW. When speaking to Didrik Fjeldstad you can hear four or five at once. The multilingual VP of brand marketing for Scandinavian Airlines sat down with MarketScale to talk about how the company is working towards cutting carbon emissions and the importance of travel to the world in terms of learning and strengthening communities with new ideas.

Andre Natera

Not everyone has to travel across an ocean to experience SXSW. Andre Natera, Executive Chef at the Fairmont Hotel Austin, walked across town to join the podcast and told us how the city collectively prepared for an influx of tourists. He also gave us a nuanced answer to the ‘local food’ trend and what restaurants consider when deciding what goes into their menu.

Tim Brown and Nigel McAlpine

Specific testimony is what makes a conference like SXSW a must-attend event. Dr. Tim Brown Consultant Transplant Surgeon at Belfast City Hospital in Northern Ireland and Nigel McAlpine, Immersive Technology lead at Digital Catapult, spoke to MarketScale about a lifesaving surgery that was made possible through new technologies in the medical field. Hear how a kidney transplant was derailed by a tumor until the surgeon and a technology company were able to save it and make it safe for donation.

Jacob Gordon

Technology and music are synonymous with Austin but not often together. Jacob Gordon has changed this with company, Artiphon. Gordon has developed a product that adapts to the way individual musicians play. Users can strum, tap, drum and slide all with one physical device and use Artiphon’s software to edit sound. He explained to us what inspired him to create a new instrument and how it might disrupt the traditional music recording industry.

Dimitrios Psaltis

Almost one century later, the scientific community is still exploring Albert Einstein’s theory of relativity. Photographing black holes is at the core of what Event Horizon Telescope is trying to accomplish and Dimitrios Psaltis, professor of astronomy and physics at the University of Arizona and EHT project scientist, elaborated on the EHT’s mission before his speaking engagement at SXSW 2019. He may not be able to give away all of his findings but he provides MarketScale with an inkling of what to expect in the near future in regards to black holes and humanity’s understanding of space.

Trak Lord

Three-dimensional printing has become a larger topic at SXSW over the last few years. The technology has captured the attention of industries from construction to healthcare and everything in between. Markforged Director of Communications Trak Lord described how the company is innovating with 3D-printed metal parts for factory floors, enabling businesses to operate at maximum capacity. He also spoke about how the company has pioneered carbon fiber printing and its implications to manufacturing businesses.

Markforged is also up for an innovation award at SXSW 2019 and Lord spoke to MarketScale about why the company was nominated.

For the latest from SXSW make sure to follow MarketScale on Twitter and Instagram @MarketScale and check out our podcast series and written content for more perspective on the conference next week!

About the author

SA
Software And Technology

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

SA
Software And Technology

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512